Preclinical (mouse models) · PMID 41533788
SIPPC oral peptide delivery platform: KPV conjugate for colitis and acute lung injury — VialBase Research
Self-Immolative Polymer-Peptide Conjugate (SIPPC) technology for oral peptide delivery
Last updated · 2025 · Various · Science (or related high-impact journal)
Key findings
- Self-Immolative Polymer-Peptide Conjugate (SIPPC) technology for oral peptide delivery
- proKPV achieved 3.8-fold greater colonic accumulation than free KPV
- Enhanced efficacy at 20-fold lower dose than free KPV
- Demonstrated GI stability, mucus penetration, and ROS-responsive release
- Also effective in acute lung injury model via oral delivery
- Platform validated with multiple peptides (KPV, Ac-QAW, IRW)
SIPPC Oral Delivery Makes KPV 20x More Potent (PMID: 41533788)
Study Design
- Novel SIPPC (Self-Immolative Polymer-Peptide Conjugate) platform
- Hydrophilic PEG segment + ROS-responsive hydrophobic module + hydrolyzable scaffold
- Self-assembles into micelle-like nanoparticles
- Tested with KPV, Ac-QAW, and IRW peptides
- Colitis and acute lung injury mouse models
Key Results
- proKPV: 3.8-fold greater colonic accumulation vs free KPV
- Enhanced efficacy at 20-fold lower dose
- Remarkable GI stability and mucus penetration
- ROS-responsive release = targeted delivery to inflamed sites
- Oral proKPV also accumulated in inflamed lungs (acute lung injury model)
- Platform works across multiple peptide types
Relevance
Game-changing delivery technology for KPV. If this translates to humans:
- Dramatically lower doses needed
- True site-specific delivery to inflamed tissue
- Extends KPV applications from gut to lung inflammation
- SIPPC platform could revolutionize oral peptide therapeutics broadly
See Also
- Parent compound: KPV